Treatments for the Metabolic Syndrome

The Metabolic Syndrome

Volumn , Issue , 2006, Pages 381-406

  Hanefeld, Markolf ^a   Schaper, Frank ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

'Ornish program'; Atherosclerotic vascular disease (AVD); Coronary Drug Project; Dietary Approaches to Stop Hypertension (DASH) trial; Insulin resistance and visceral obesity; Lifestyle intervention in hypertension; Polypharmacy; Statins LDL cholesterol lowering drugs

Indexed keywords

EID: 84889848085     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470025131.ch15     Document Type: Chapter

References (107)

1. Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M.; PRINCE Investigators. 2001. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA, 286 (1), 64-70.
2. Alberti, K. G., Zimmet, P. Z. 1998. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med., 15 (7), 539-553.
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. 2002. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288 (23), 2981-2997. [Errata in: JAMA, 2003, 289 (2), 178, JAMA, 2004, 291 (18), 2196.]
4. Anderssen, S. A., Hjermann, I., Urdal, P., Torjesen, P. A., Holme, I. 1996. Improved carbohydrate metabolism after physical training and dietary intervention in individuals with the 'atherothrombogenic syndrome'. Oslo Diet and Exercise Study (ODES). A randomized trial. J. Intern. Med., 240 (4), 203-209.
5. Anonymous. 1975. Clofibrate and niacin in coronary heart disease. JAMA, 231 (4), 360-381.
6. Anonymous. 1992. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA, 267 (9), 1213-1220. [Erratum in: JAMA, 1992, 267 (17), 2330.]
7. Appel, L. J., Miller 3rd, E. R., Seidler, A. J., Whelton, P. K. 1993. Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials. Arch. Intern. Med, 153 (12), 1429-1438.
8. Barzilay, J. I., Davis, B. R., Bettencourt, J., Margolis, K. L., Goff, J., D. C., Black, H., Habib, G., Ellsworth, A., Force, R. W., Wiegmann, T., Ciocon, J. O., Basile, J. N.; ALLHAT Collaborative Research Group. 2004. Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J. Clin. Hypertens. (Greenwich), 6 (3), 116-125.
9. Bonora, E., Formentini, G., Calcaterra, F., Lombardi, S., Marini, F., Zenari, L., Saggiani, F., Poli, M., Perbellini, S., Raffaelli, A., Cacciatori, V., Santi, L., Targher, G., Bonadonna, R., Muggeo, M. 2002. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care, 25 (7), 1135-1141.
10. Bonow, R. O., Eckel, R. H. 2003. Diet, obesity, and cardiovascular risk. N. Engl. J. Med., 348 (21), 2057-2058.
11. Brehm, B. J., Seeley, R. J., Daniels, S. R., D'Alessio, D. A. 2003. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. J. Clin. Endocrinol. Metab, 88 (4., 1617-1623.
12. Brown, C. D., Higgins, M., Donato, K. A., Rohde, F. C., Garrison, R., Obarzanek, E., Ernst, N. D., Horan, M. 2000. Body mass index and the prevalence of hypertension and dyslipidemia. Obes. Res., 8 (9), 605-619.
13. Brown, S. L., Sobel, B. E., Fujii, S. 1995. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. Circulation, 92 (4), 767-772.
14. Campbell, I. W. 2000. Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? Drugs, 60 (5), 1017-1028.
15. Carey, D. G., Cowin, G. J., Galloway, G. J., Jones, N. P., Richards, J. C., Biswas, N., Doddrell, D. M. 2002. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes. Res., 10 (10), 1008-10015. [Erratum in: Obes Res., 2002, 10 (11), after table of contents.]
16. Cassano, P. A., Segal, M. R., Vokonas, P. S., Weiss, S. T. 1990. Body fat distribution, blood pressure, and hypertension. A prospective cohort study of men in the normative aging study. Ann. Epidemiol., 1 (1), 33-48.
17. Chesney, C. M., Elam, M. B., Herd, J. A., Davis, K. B., Garg, R., Hunninghake, D., Kennedy, J. W., Applegate, W. B. 2000. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am. Heart. J., 140 (4), 631-636.
18. Chiasson, J. L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M.; STOP-NIDDM Trial Research Group. 2003. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA, 290 (4), 486-494.
19. Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., Fuller, J. H.; CARDS investigators. 2004. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 364 (9435), 685-696.
20. Cook, S., Weitzman, M., Auinger, P., Nguyen, M., Dietz, W. H. 2003. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch. Pediatr. Adolesc. Med., 157 (8), 821-827.
21. Costa, A., Casamitjana, R., Casals, E., Alvarez, L., Morales, J., Masramon, X., Hernandez, G., Gomis, R., Conget, I. 2003. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet. Med, 20 (9), 743-745.
22. Dagenais, G. R., Yusuf, S., Bourassa, M. G., Yi, Q., Bosch, J., Lonn, E. M., Kouz, S., Grover, J.; HOPE Investigators. 2001. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation, 104 (5), 522-526.
23. DeFronzo, R. A., Goodman, A. M. 1995. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N. Engl. J. Med, 333 (9), 541-549.
24. Despres, J. P., Moorjani, S., Ferland, M., Tremblay, A., Lupien, P. J., Nadeau, A., Pinault, S., Theriault, G., Bouchard, C. 1989. Adipose tissue distribution and plasma lipoprotein levels in obese women. Importance of intra-abdominal fat. Arteriosclerosis, 9 (2), 203-210.
25. Dujovne, C. A., Zavoral, J. H., Rowe, E., Mendel, C. M.; Silbutramine Study Group. 2001. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am. Heart. J, 142 (3), 489-497.
26. Elam, M. B., Hunninghake, D. B., Davis, K. B., Garg, R., Johnson, C., Egan, D., Kostis, J. B., Sheps, D. S., Brinton, E. A. 2000. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA, 284 (10), 1263-1270.
27. Elkeles, R. S., Diamond, J. R., Poulter, C., Dhanjil, S., Nicolaides, A. N., Mahmood, S., Richmond, W., Mather, H., Sharp, P., Feher, M. D. 1998. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care, 21 (4), 641-648.
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP. III). JAMA, 285, 2486-2497.
29. Ferrari, P., Rosman, J., Weidmann, P. 1991. Antihypertensive agents, serum lipoproteins and glucose metabolism. Am. J. Cardiol., 67 (10), 26B-35B.
30. Foster, G. D., Wyatt, H. R., Hill, J. O., McGuckin, B. G., Brill, C., Mohammed, B. S., Szapary, P. O., Rader, D. J., Edman, J. S., Klein, S. 2003. A randomized trial of a low-carbohydrate diet for obesity. N. Engl. J. Med., 348 (21), 2082-2090.
31. Freed, M. I., Ratner, R., Marcovina, S. M., Kreider, M. M., Biswas, N., Cohen, B. R., Brunzell, J. D.; Rosiglitazone Study, 108 investigators. 2002. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am. J. Cardiol., 90 (9), 947-952.
32. Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., Packard, C. J., Shepherd, J., Gaw, A. 2001. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation, 103 (3), 357-362.
33. Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V. 1987. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med., 317 (20), 1237-1245.
34. Frost, G., Leeds, A. A., Dore, C. J., Madeiros, S., Brading, S., Dornhorst, A. 1999. Glycaemic index as a determinant of serum HDL-cholesterol concentration. Lancet, 353 (9158), 1045-1048.
35. Garg, A. 1998. High-monounsaturated-fat diets for patients with diabetes mellitus: a meta-analysis. Am. J. Clin. Nutr., 67 (3 Suppl.), 577S-582S.
36. Grossman, E. 2003. Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G. Bakris, et al. J. Hum. Hypertens., 17 (1), 5-6.
37. Grundy, S. M., Mok, H. Y., Zech, L., Berman, M. 1981. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J. Lipid. Res., 22 (1), 24-36.
38. Haffner, S. M., Greenberg, A. S., Weston, W. M., Chen, H., Williams, K., Freed, M. I. 2002. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation, 106 (6), 679-684.
39. Hanefeld, M., Leonhardt, W. 1981. Das metabolische Syndrom. Dtsch. Gesundheitwes. 36, 545-551.
40. Hanefeld, M., Leonhardt, W. 1997. The Metabolic Syndrome. Gustav Fischer: Berlin.
41. Hanefeld, M., Schmechel, H., Julius, U. and the DIS group. 1991. Five year incidence of coronary heart disease related to major risk factors and metabolic control in newly diagnosed non-insulin-dependent diabetes. The diabetes intervention study (DIS). Nutr. Metab. Cardiovasc. Dis., 1, 135-140.
42. Hanefeld, M., Cagatay, M., Petrowitsch, T., Neuser, D., Petzinna, D., Rupp, M. 2004. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: metaanalysis of seven long-term studies. Eur. Heart J., 25 (1), 10-16.
43. Isomaa, B., Almgren, P., Tuomi, T., Forsen, B., Lahti, K., Nissen, M., Taskinen, M. R., Groop, L. 2001. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24 (4), 683-689.
44. Jacob, S., Rett, K., Henriksen, E. J. 1998. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am. J. Hypertens., 11 (10), 1258-1265.
45. Jin, F. Y., Kamanna, V. S., Kashyap, M. L. 1997. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol., 17 (10), 2020-2028.
46. Kashyap, M. L., McGovern, M. E., Berra, K., Guyton, J. R., Kwiterovich, P. O., Harper, W. L., Toth, P. D., Favrot, L. K., Kerzner, B., Nash, S. D., Bays, H. E., Simmons, P. D. 2002. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am. J. Cardiol., 89 (6), 672-678.
47. Katzel, L. I., Bleecker, E. R., Colman, E. G., Rogus, E. M., Sorkin, J. D., Goldberg, A. P. 1995. Effects of weight loss vs aerobic exercise training on risk factors for coronary disease in healthy, obese, middle-aged and older men. A randomized controlled trial. JAMA, 274 (24), 1915-1921.
48. Katzmarzyk, P. T., Leon, A. S., Wilmore, J. H., Skinner, J. S., Rao, D. C., Rankinen, T., Bouchard, C. 2003. Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study. Med. Sci. Sports Exerc. 35 (10), 1703-1709.
49. Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J., Hollander, P. 2002. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care, 25 (6), 1033-1041. [Erratum in: Diabetes Care, 2003, 26 (3), 971.]
50. Knopp, R. H. 1999. Drug treatment of lipid disorders. N. Engl. J. Med., 341 (7), 498-511.
51. Knopp, R. H., Walden, C. E., Retzlaff, B. M., McCann, B. S., Dowdy, A. A., Albers, J. J., Gey, G. O., Cooper, M. N. 1997. Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men. The Dietary Alternatives Study. JAMA, 278 (18), 1509-1515.
52. Knopp, R. H., Alagona, P., Davidson, M., Goldberg, A. C., Kafonek, S. D., Kashyap, M., Sprecher, D., Superko, H. R., Jenkins, S., Marcovina, S. 1998. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism, 47 (9), 1097-1104.
53. Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., Nathan, D. M.; Diabetes Prevention Program Research Group. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med., 346 (6), 393-403.
54. Koertge, J., Weidner, G., Elliott-Eller, M., Scherwitz, L., Merritt-Worden, T. A., Marlin, R., Lipsenthal, L., Guarneri, M., Finkel, R., Saunders, Jr, D. E., McCormac, P., Scheer, J. M., Collins, R. E., Ornish, D. 2003. Improvement in medical risk factors and quality of life in women and men with coronary artery disease in the Multicenter Lifestyle Demonstration Project. Am. J. Cardiol, 91 (11), 1316-1322.
55. Koskinen, P., Manttari, M., Manninen, V., Huttunen, J. K., Heinonen, O. P., Frick, M. H. 1992. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care, 15 (7), 820-825.
56. Lee, K. W., Lip, G. Y. 2003. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch. Intern. Med., 163 (19), 2368-2392.
57. Liao, D., Asberry, P. J., Shofer, J. B., Callahan, H., Matthys, C., Boyko, E. J., Leonetti, D., Kahn, S. E., Austin, M., Newell, L., Schwartz, R. S., Fujimoto, W. Y. 2002. Improvement of BMI, body composition, and body fat distribution with lifestyle modification in Japanese Americans with impaired glucose tolerance. Diabetes Care, 25 (9), 1504-1510.
58. Lindholm, L. H., Ibsen, H., Dahlof, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., Lederballe-Pedersen, O., Nieminen, M. S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J., Snapinn, S.; LIFE Study Group. 2002. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359 (9311), 1004-1010.
59. Mann, J. F., Gerstein, H. C., Yi, Q. L., Franke, J., Lonn, E. M., Hoogwerf, B. J., Rashkow, A., Yusuf, S.; HOPE Investigators. 2003. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am. J. Kidney Dis., 42 (5), 936-942.
60. Manson, J. E., Willett, W. C., Stampfer, M. J., Colditz, G. A., Hunter, D. J., Hankinson, S. E., Hennekens, C. H., Speizer, F. E. 1995. Body weight and mortality among women. N. Engl. J. Med, 333 (11), 677-685.
61. Mavri, A., Stegnar, M., Krebs, M., Sentocnik, J. T., Geiger, M., Binder, B. R. 1999. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler. Thromb. Vasc. Biol., 19 (6), 1582-1587.
62. McGarry, J. D. 1992. What if Minkowski had been ageusic? An alternative angle on diabetes. Science, 258 (5083), 766-770.
63. McGill, Jr, H. C., McMahan, C. A., Herderick, E. E., Zieske, A. W., Malcom, G. T., Tracy, R. E., Strong, J. P.; Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. 2002. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation, 105 (23), 2712-2718.
64. McKenney, J. M., Proctor, J. D., Harris, S., Chinchili, V. M. 1994. A comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemic patients. JAMA, 271 (9), 672-677.
65. Meyers, C. D., Kashyap, M. L. 2004. Management of the metabolic syndrome-nicotinic acid. Endocrinol. Metab. Clin. North Am., 33 (3), 557-575.
66. Muls, E., Kolanowski, J., Scheen, A., Van Gaal, L.; ObelHyx Study Group. 2001. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int. J. Obes. Relat. Metab. Disord, 25 (11), 1713-1721.
67. Ornish, D., Brown, S. E., Scherwitz, L. W., Billings, J. H., Armstrong, W. T., Ports, T. A., McLanahan, S. M., Kirkeeide, R. L., Brand, R. J., Gould, K. L. 1990. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet, 1990 336 (8708), 129-133.
68. Pan, X. R., Li, G. W., Hu, Y. H., Wang, J. X., Yang, W. Y., An, Z. X., Hu, Z. X., Lin, J., Xiao, J. Z., Cao, H. B., Liu, P. A., Jiang, X. G., Jiang, Y. Y., Wang, J. P., Zheng, H., Zhang, H., Bennett, P. H., Howard, B. V. 1997. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care, 1997 20 (4), 537-544.
69. Pischon, T., Hankinson, S. E., Hotamisligil, G. S., Rifai, N., Rimm, E. B. 2003. Leisure-time physical activity and reduced plasma levels of obesity-related inflammatory markers. Obes. Res, 11 (9), 1055-1064.
70. Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., Liang, T. J., Yanovski, J. A., Kleiner, D. E., Hoofnagle, J. H. 2004. A pilot study of pioglitazone treatment for nonalcoholic steato-hepatitis. Hepatology, 2004 39 (1), 188-196.
71. Raji, A., Seely, E. W., Bekins, S. A., Williams, G. H., Simonson, D. C. 2003. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care, 26 (1), 172-178.
72. Ridker, P. M., Buring, J. E., Cook, N. R., Rifai, N. 2003. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation, 107 (3), 391-397.
73. Robins, S. J., Rubins, H. B., Faas, F. H., Schaefer, E. J., Elam, M. B., Anderson, J. W., Collins, D.; Veterans Affairs HDL Intervention Trial (VA-HIT). 2003. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care, 26 (5), 1513-1517.
74. Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., Wilt, T. J., Wittes, J. 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med, 341 (6), 410-418.
75. Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha, D., Obarzanek, E., Conlin, P. R., Miller, 3rd, E. R. Simons-Morton, D. G., Karanja, N., Lin, P. H.; DASH-Sodium Collaborative Research Group. 2001. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N. Engl. J. Med., 344 (1), 3-10.
76. Sacks, F. M., Tonkin, A. M., Craven, T., Pfeffer, M. A., Shepherd, J., Keech, A., Furberg, C. D., Braunwald, E. 2002. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation, 105 (12), 1424-1428.
77. Samaha, L. L., Iqbal, N., Seshandri, P., Chicano, K. L., Daily, D. A., McGrory, J. 2003. A low carbohydrate as compared with a low-fat diet in severe obesity. N. Engl. J. Med., 289 1837-1850.
78. Sattar, N., Gaw, A., Scherbakova, O., Ford, I., O'Reilly, D. S., Haffner, S. M., Isles, C., Macfarlane, P. W., Packard, C. J., Cobbe, S. M., Shepherd, J. 2003. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation, 108 (4), 414-419.
79. Scheen, A. J. 2004. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs, 64 (22), 2537-2565.
80. Shepherd, J., Packard, C. J., Patsch, J. R., Gotto Jr, A. M., Taunton, O. D. 1979. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J. Clin. Invest., 63 (5), 858-867.
81. Shepherd, J., Cobbe, S. M., Ford, I. et al. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N. Engl. J. Med, 333, 1301-1307.
82. Shields, T. M., Hennekens, C. H. 2004. Management of metabolic syndrome: aspirin. Endocrinol. Metab. Clin. North Am., 33 (3), 577-593.
83. Sica, D. A., Bakris, G. L. 2002. Type 2 diabetes: RENAAL and IDNT-the emergence of new treatment options. J. Clin. Hypertens. (Greenwich), 4 (1), 52-57.
84. Slentz, C. A., Duscha, B. D., Johnson, J. L., Ketchum, K., Aiken, L. B., Samsa, G. P., Houmard, J. A., Bales, C. W., Kraus, W. E. 2004. Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE-a randomized controlled study. Arch. Intern. Med., 164 (1), 31-39.
85. Sowers, J. R. 2003. Effects of statins on the vasculature: Implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am. J. Cardiol., 91 (4A), 14B-22B.
86. Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., Fruchart, J. C. 1998. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 1998 98 (19), 2088-2093.
87. Staessen, J., Fagard, R., Lijnen, P., Amery, A. 1989. Body weight, sodium intake and blood pressure. Body weight, sodium intake and blood pressure. J. Hypertens. Suppl. 7 (1), S19-S23.
88. Stamler, J., Rose, G., Stamler, R., Elliott, P., Dyer, A., Marmot, M. 1989. INTERSALT study findings. Public health and medical care implications. Hypertension, 14 (5), 570-577.
89. Steiner, G. 2001. The use of fibrates and of statins in preventing atherosclerosis in diabetes. Curr. Opin. Lipidol., 12 (6), 611-617.
90. Steiner, G. 2004. Fibrates in the metabolic syndrome and in diabetes. Endocrinol. Metab. Clin. North Am., 33 (3), 545-555.
91. Stern, M. P. 1995. Diabetes and cardiovascular disease. The 'common soil' hypothesis. Diabetes, 44 (4), 369-374.
92. Stone, N. J. 2004. Focus on lifestyle change and the metabolic syndrome. Endocrinol. Metab. Clin. North Am., 33 (3), 493-508.
93. Su, H. Y., Sheu, W. H., Chin, H. M., Jeng, C. Y., Chen, Y. D., Reaven, G. M. 1995. Effect of weight loss on blood pressure and insulin resistance in normotensive and hypertensive obese individuals. Am. J. Hypertens. 8 (11), 1067-1071.
94. Tan, K. C., Chow, W. S., Tam, S. C., Ai, V. H., Lam, C. H., Lam, K. S. 2002. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab., 87 (2), 563-568.
95. Torgerson, J. S., Hauptman, J., Boldrin, M. N., Sjostrom, L. 2004. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27 (1), 155-161. [Erratum in: Diabetes Care, 2004, 27 (3), 856.]
96. Tuomilehto, J., Lindstrom, J., Eriksson, J. G., Valle, T. T., Hamalainen, H., Ilanne-Parikka, P., Keinanen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., Salminen, V., Uusitupa, M.; Finnish Diabetes Prevention Study Group. 2001. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med, 344 (18), 1343-1350.
97. UK Prospective Diabetes Study Group. 1998a. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352 (9131), 854-865. [Erratum in: Lancet, 1998, 352 (9139), 1557.]
98. UK Prospective Diabetes Study Group. 1998b. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ, 317 (7160), 713-720.
99. Vakkilainen, J., Steiner, G., Ansquer, J. C., Aubin, F., Rattier, S., Foucher, C., Hamsten, A., Taskinen, M. R.; DAIS Group. 2003. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation, 107 (13), 1733-1737.
100. Wannamethee, S. G., Lowe, G. D., Whincup, P. H., Rumley, A., Walker, M., Lennon, L. 2002. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation, 105 (15), 1785-1790.
101. Watts, G. F., Lewis, B., Brunt, J. N., Lewis, E. S., Coltart, D. J., Smith, L. D., Mann, J. I., Swan, A. V. 1992. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet, 339 (8793), 563-569.
102. Whelton, P. K., Appel, L. J., Espeland, M. A., Applegate, W. B., Ettinger, Jr, W. H., Kostis, J. B., Kumanyika, S., Lacy, C. R., Johnson, K. C., Folmar, S., Cutler, J. A. 1998. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA, 279 (11), 839-846. [Erratum in: JAMA, 279 (24), 1954.]
103. Whelton, S. P., Chin, A., Xin, X., He, J. 2002. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann. Intern. Med, 136 (7), 493-503.
104. Wilson, P. W., Kannel, W. B., Silbershatz, H., D'Agostino, R. B. 1999. Clustering of metabolic factors and coronary heart disease. Arch. Intern. Med, 159 (10., 1104-1109.
105. Wing, R. R., Hill, J. O. 2001. Successful weight loss maintenance. Annu. Rev. Nutr., 21, 323-341.
106. Xydakis, A. M., Ballantyne, C. M. 2004. Management of metabolic syndrome: statins. Endocrinol. Metab. Clin. North Am., 33 (3), 509-523.
107. Yusuf, S., Gerstein, H., Hoogwerf, B., Pogue, J., Bosch, J., Wolffenbuttel, B. H., Zinman, B.; HOPE Study Investigators. 2001. Ramipril and the development of diabetes. JAMA, 286 (15), 1882-1885.